Mga Batayang Estadistika
| LEI | 549300VI8WO8GK5QK793 |
| CIK | 1175151 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cytosorbents Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 20, 2025 |
Exhibit 99.1 CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J., August 20, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit a |
|
| August 7, 2025 |
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update PRINCETON, N. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 Cytosorbents Corp (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| August 1, 2025 |
Exhibit 99.1 CytoSorbents Leads a New Era in Sepsis Treatment CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th PRINCETON, N.J., July 31, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and ca |
|
| July 2, 2025 |
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR Exhibit 99.1 CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR PRINCETON, N.J., July 2, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Dru |
|
| July 2, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| June 24, 2025 |
Exhibit 99.1 CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR PRINCETON, N.J., June 24, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory revie |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| May 14, 2025 |
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update PRINCETON, N.J., May 14, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 1, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
CytoSorbents Provides Regulatory Update for DrugSorb-ATR CytoSorbents Provides Regulatory Update for DrugSorb-ATR PRINCETON, N.J., May 1, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. DrugSorb-ATR is designed to reduce the severity of bleed |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 17, 2025 |
EXHIBIT 99.1 CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 —CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-thre |
|
| April 17, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 15, 2025 |
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America Exhibit 99.1 CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America PRINCETON, N.J., April 14, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North Ameri |
|
| April 15, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 4, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| April 4, 2025 |
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants Exhibit 99.1 CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants PRINCETON, NJ, April 4, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the “Series B Right Warrants”) |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 CYTOSORBENTS CORPORATION (Exac |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2025 |
EXHIBIT 99.1 CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights · 2024 marked by strong commercial execution and improved operating leverage · Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 · Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet · Strengt |
|
| March 31, 2025 |
Exhibit 19.1 CYTOSORBENTS CORPORATION AMENDED AND RESTATED INSIDER TRADING POLICY Adopted December 9, 2024 I.Purpose This Insider Trading Policy (this “Policy”) provides the standards of CytoSorbents Corporation (the "Company") with respect to transactions in Company securities, or securities of other publicly-traded companies, while in possession of material, non-public information. In addition, |
|
| March 21, 2025 |
EXHIBIT 99.1 CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 21, 2025 — CytoSorbents Corporatio |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 21, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| March 4, 2025 |
Exhibit 99.1 CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 4, 2025 — Cyto |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| February 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 25, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2025 |
EXHIBIT 99.1 CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants 1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds PRINCETON, NJ, February 25, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| January 13, 2025 |
EX-99.1 2 tm253092d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, NJ, January 13, 2025 — CytoSorbents Corporation |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| January 6, 2025 |
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai Exhibit 99.1 CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai PRINCETON, NJ, January 6, 2025 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the opening of a new regional sales subsidiary in Dubai, United Arab Emira |
|
| January 3, 2025 |
Exhibit 99.1 CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, NJ, January 3, 2025 — Cy |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2025 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| December 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 23, 2024 |
EXHIBIT 99.1 CytoSorbents Rights Offering Begins To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025 PRINCETON, NJ, December 23, 2024 — CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement press release. S |
|
| December 9, 2024 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| December 9, 2024 |
Form of Subscription Right Warrant Certificate Exhibit 4.1 RIGHTS CERTIFICATE #: NUMBER OF RIGHTS THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED , 2024 (THE "PROSPECTUS") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT. CytoSorbents Corporation Incorporated under the laws of the State of Delaware NON |
|
| December 9, 2024 |
Exhibit 99.7 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED , 2024 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT, BY CALLING (800) 549-6864 (TOLL-FREE) OR (212) 269-5550 (BROKER-DEALERS AND NOMINEES) OR BY EMAIL AT [email protected]. CY |
|
| December 9, 2024 |
Exhibit 99.2 THE TERMS AND CONDITIONS OF THE OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED , 202 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT, BY CALLING (800) 549-6864 (TOLL-FREE) OR (212) 269-5550 (BROKER-DEALERS AND NOMINEES) OR BY EMAIL AT [email protected]. FORM OF IN |
|
| December 9, 2024 |
Exhibit 99.3 FORM OF LETTER TO STOCKHOLDERS AND CERTAIN ELIGIBLE WARRANTHOLDERS WHO ARE RECORD HOLDERS CYTOSORBENTS CORPORATION 6,250,000 Units Offered Pursuant to Subscription Rights Distributed to Stockholders of CytoSorbents Corporation , 2024 Dear Stockholders: Enclosed are materials relating to the rights offering being conducted by CytoSorbents Corporation, a Delaware corporation, including |
|
| December 9, 2024 |
PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (To Prospectus dated September 30, 2024) Registration Statement No. |
|
| December 9, 2024 |
Exhibit 99.1 THE TERMS AND CONDITIONS OF THE OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED , 202 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT, BY CALLING (800) 549-6864 (TOLL-FREE) OR (212) 269-5550 (BROKER-DEALERS AND NOMINEES) OR BY EMAIL AT [email protected]. FORM OF IN |
|
| December 9, 2024 |
EXHIBIT 99.9 CytoSorbents Announces Rights Offering Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday December 13, 2024 to Participate PRINCETON, NJ, December 9, 2024 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the details |
|
| December 9, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 9, 2024 |
CYTOSORBENTS CORPORATION BENEFICIAL OWNER ELECTION FORM Exhibit 99.6 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED , 202 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT, BY CALLING (212) 269-5550 (BANKERS AND BROKERS) OR (800) 549-6864 (ALL OTHERS TOLL-FREE) OR BY EMAIL AT [email protected]. |
|
| December 9, 2024 |
Exhibit 99.4 FORM OF LETTER TO BROKERS AND OTHER NOMINEE HOLDERS CYTOSORBENTS CORPORATION 6,250,000 Units Offered Pursuant to Subscription Rights Distributed to Stockholders of CytoSorbents Corporation , 2024 To Securities Dealers, Commercial Banks, Trust Companies and Other Nominees: This letter is being distributed to securities dealers, commercial banks, trust companies and other nominees in co |
|
| December 9, 2024 |
Exhibit 99.5 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEE HOLDERS CYTOSORBENTS CORPORATION 6,250,000 Units Offered Pursuant to Subscription Rights Distributed to Stockholders of CytoSorbents Corporation , 2024 To Our Clients: Enclosed for your consideration are (i) a prospectus, dated December 9, 2024 (the “Prospectus”), (ii) “Instructions as to Use of CytoSorbents Corporation Non-Transf |
|
| December 9, 2024 |
FORM OF NOTICE OF IMPORTANT TAX INFORMATION CYTOSORBENTS CORPORATION Exhibit 99.8 FORM OF NOTICE OF IMPORTANT TAX INFORMATION CYTOSORBENTS CORPORATION This notice is provided in connection with the prospectus of CytoSorbents Corporation (the “Company”) dated , 2024. Under the U.S. federal income tax laws, distributions (including constructive distributions) that may be made by the Company of certain non-transferable subscription right warrants (the “Subscription Ri |
|
| December 9, 2024 |
Form of Series A Right Warrant Certificate Exhibit 4.2 RIGHTS CERTIFICATE #: NUMBER OF RIGHTS THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED , 2024 (THE "PROSPECTUS") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT. CytoSorbents Corporation Incorporated under the laws of the State of Delaware TRAN |
|
| December 9, 2024 |
Exhibit 1.1 DEALER-MANAGER AGREEMENT December 9, 2024 Moody Capital Solutions, Inc. As Dealer-Manager 2458 Dunkerrin Lane Atlanta, GA 30360 Attention: Richard H. Kreger Ladies and Gentlemen: The following will confirm our agreement relating to the proposed offering (the “Offering”) to be undertaken by CytoSorbents Corporation, a Delaware corporation (the “Company”), pursuant to which the Company w |
|
| December 9, 2024 |
Form of Series B Right Warrant Certificate Exhibit 4.3 RIGHTS CERTIFICATE #: NUMBER OF RIGHTS THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS DATED , 2024 (THE "PROSPECTUS") AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM D.F. KING & CO., INC., THE INFORMATION AGENT. CytoSorbents Corporation Incorporated under the laws of the State of Delaware TRAN |
|
| November 14, 2024 |
CTSO / Cytosorbents Corporation / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Cytosorbents Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 23283X206 (CUSIP Number) September 30, 2024 (Date |
|
| November 7, 2024 |
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results Exhibit 99.1 CytoSorbents Reports Third Quarter 2024 Financial and Operational Results PRINCETON, N.J., November 7, 2024 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. T |
|
| November 7, 2024 |
Amendment to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. Exhibit 10.1 AMENDMENT NO. 2024-1 TO CYTOSORBENTS CORPORATION AMENDED AND RESTATED 2014 LONG-TERM INCENTIVE COMPENSATION PLAN April 19, 2024 WHEREAS, CytoSorbents Corporation, a Delaware corporation (the “Company”), maintains the Company’s Amended and Restated 2014 Long-Term Incentive Plan, effective as of April 12, 2019 (the “Plan”) for the benefit of eligible employees of the Company or its subs |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| October 1, 2024 |
Up to $20,000,000 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2024) Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| October 1, 2024 |
Exhibit 99.1 CytoSorbents Submits DrugSorb™-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • The De Novo medical device application for DrugSorb™-ATR is eligible for FDA priority review as an FDA Breakthrough Designated Device for this indication • The Health Canada Medical Devic |
|
| October 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| September 27, 2024 |
CytoSorbents Corporation 305 College Road East Princeton, New Jersey 08540 (732) 329-8885 CytoSorbents Corporation 305 College Road East Princeton, New Jersey 08540 (732) 329-8885 September 27, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 26, 2024 |
As filed with the Securities and Exchange Commission on September 26, 2024. As filed with the Securities and Exchange Commission on September 26, 2024. Registration No. 333-281062 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTOSORBENTS CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 98-0373793 (State or Other Jurisdiction of Incorpor |
|
| August 20, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2024 |
Exhibit 10.4 Inducement Grant CYTOSORBENTS CORPORATION Nonstatutory Stock Option Notice Grant No.: This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, Peter J. Mariani, subject to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchase shares |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2024 |
Exhibit 10.5 Kathleen P. Bloch 206 E. Washington Ave. Wildwood Crest, NJ 08260 732-921-0149 Consulting Agreement THIS AGREEMENT (The “Agreement”) entered into as of August 13, 2024 between Kathleen P. Bloch (“Consultant”) and CytoSorbents Corporation and its wholly-owned subsidiary CytoSorbents Medical, Inc., both Delaware corporations, with offices at 305 College Road East, Princeton, NJ 08540 (c |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
Exhibit 10.2 Inducement Grant Restricted Stock Unit Agreement Grantee: Peter J. Mariani No. of RSUs: 350,000 This Agreement (the “Agreement”), dated as of August 14, 2024 (the “Grant Date”) is delivered by CytoSorbents Corporation, a Delaware corporation (the “Company”) to you, Peter J. Mariani. Pursuant to the terms of the Employment Agreement, dated August 14, 2024 between the Company and you ( |
|
| August 16, 2024 |
Employment Agreement, dated August 14, 2024, by and between the Company and Mr. Peter J. Mariani Exhibit 10.1 Executive Employment Agreement This Executive Employment Agreement (the “Employment Agreement” or “Agreement”) is made and entered by and between Peter J. Mariani (the “Executive”), and CytoSorbents Medical, Inc., on behalf of itself, its parent CytoSorbents Corporation, and all other affiliates and subsidiaries thereof (collectively, the “Company”), effective as of August 14, 2024 (t |
|
| August 16, 2024 |
Exhibit 99.1 CytoSorbents Appoints Peter J. Mariani Chief Financial Officer CytoSorbents CFO Kathleen P. Bloch Retires PRINCETON, N.J., August 13, 2024 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CytoSorbents Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 16, 2024 |
Exhibit 10.3 Inducement Grant CYTOSORBENTS CORPORATION Nonstatutory Stock Option Notice Grant No.: This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, Peter J. Mariani, subject to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchase shares of c |
|
| August 14, 2024 |
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results Exhibit 99.1 CytoSorbents Reports Second Quarter 2024 Financial and Operational Results · New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. Bloch · On track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarter · In Q2 2024, increased product sales by 10% and reduced operating loss by 48% · Achieved more than a quarter million CytoSorb treatments cumula |
|
| August 14, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| August 1, 2024 |
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., August 1, 2024 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained compliance with the Nasdaq Stock Ma |
|
| August 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 26, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024. As filed with the Securities and Exchange Commission on July 26, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTOSORBENTS CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 98-0373793 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. |
|
| July 26, 2024 |
Up to $19,700,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-257910 AMENDMENT NO. 1 DATED July 26, 2024 to Prospectus Supplement dated December 30, 2021 (To Prospectus dated July 27, 2021) Up to $19,700,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated December 30, 2021 (the “ATM Prospectus Supplement”). This Amendment should be read |
|
| July 26, 2024 |
Exhibit 4.5 CytoSorbents CORPORATION INDENTURE Dated as of [·] [·] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Gu |
|
| July 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) CYTOSORBENTS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| July 5, 2024 |
Exhibit 10.2 Certain portions of this exhibit have been redacted because the information is both (i) not material and (ii) the type that the registrant treats as private or confidential. Redacted information has been noted in this document with a placeholder identified by the mark “[*]”. SUPPLEMENT to the Loan and Security Agreement dated as of June 28, 2024 among CYTOSORBENTS CORPORATION (“Parent |
|
| July 5, 2024 |
Exhibit 10.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OP |
|
| July 5, 2024 |
Exhibit 99.1 CytoSorbents Secures $20 Million Credit Facility Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR in the U.S. and Canada PRINCETON, N.J., July 2, 2024 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threaten |
|
| July 5, 2024 |
Exhibit 10.1 Certain portions of this exhibit have been redacted because the information is both (i) not material and (ii) the type that the registrant treats as private or confidential. Redacted information has been noted in this document with a placeholder identified by the mark “[*]”. LOAN AND SECURITY AGREEMENT Dated as of June 28, 2024 among CYTOSORBENTS CORPORATION, a Delaware corporation, ( |
|
| June 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| May 22, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| May 9, 2024 |
CytoSorbents Reports First Quarter 2024 Results Exhibit 99.1 CytoSorbents Reports First Quarter 2024 Results · Product Sales up a robust 14% over prior year, and a significant 22% sequentially · Enhanced profitability with gross margins that surged an absolute 8% to reach 76%, reflecting stronger operational efficiencies · STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft ( |
|
| May 6, 2024 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF CYTOSORBENTS CORPORATION (as of May 2, 2024) ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be determined from time to time by the Board of Directors or, if not determined by the Board of Directors, by the Chairman of the Board, the Presi |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 3, 2024 |
Form of Nonqualified Stock Option Agreement Exhibit 10.2 US Form CYTOSORBENTS CORPORATION Nonstatutory Stock Option Notice Grant No.: This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchase shares of common stock, par va |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 29, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2024 |
Form of Payment Reduction Agreement. Exhibit 10.1 March 29, 2024 [Name] [Address of Employee] Re: Salary Reduction Agreement Dear : We are sending you this letter to memorialize your election to reduce your annual base salary by 15% to $[Amount] (your “Reduced Pay”), which represents a reduction in the amount of $[Amount] (“Reduction Amount”), effective for the period of April 1, 2024 through December 31, 2024 (the “Reduction Period” |
|
| March 15, 2024 |
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results Exhibit 99.1 CytoSorbents Reports Fourth Quarter and Full Year 2023 Results · STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 · CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year · CytoSorb core sales increased approximate |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 CYTOSORBENTS CORPORATION (Exac |
|
| March 15, 2024 |
Exhibit 21.1 CytoSorbents Corporation List of Subsidiaries Name Jurisdiction CytoSorbents Medical Inc.* Delaware CytoSorbents Europe GmbH* Germany CytoSorbents Switzerland** Switzerland CytoSorbents Poland Sp. z.o.o.** CytoSorbents Medical UK Limited** Poland United Kingdom and Republic of Ireland CytoSorbents France SAS France CytoSorbents UK Limited*** CytoSorbents India Private Limited*** Unite |
|
| March 15, 2024 |
Compensation Recoupment Policy Exhibit 97.1 CYTOSORBENTS CORPORATION COMPENSATION RECOUPMENT POLICY I. Purpose. The Board of Directors (“Board”) of CytoSorbents Corporation (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) in order to implement a mandatory clawback policy in the event of a Restatement in compliance with the Applicable Rules. Any capitalized terms used, but not immediately defined, |
|
| March 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2024 |
CTSO / Cytosorbents Corporation / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Cytosorbents Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 23283X206 (CUSIP Number) December 31, 2023 (Date |
|
| January 17, 2024 |
Exhibit 99.1 Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction PRINCETON, N.J., January 17, 2024 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 17, 2024 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
CTSO / Cytosorbents Corporation / Skylands Capital, LLC - CYTOSORBENTS CORP Passive Investment SC 13G 1 sky86895-cyto13g.htm CYTOSORBENTS CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoSorbents Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 23283X206 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| December 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 28, 2023 |
Exhibit 99.1 CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation PRINCETON, N.J., December 28, 2023 —CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, tod |
|
| December 13, 2023 |
Exhibit 99.1 CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering Company insiders participated in the transaction with $435,000 of investment PRINCETON, N.J., December 13, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer |
|
| December 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 11, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 11, 2023 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-257910 PROSPECTUS SUPPLEMENT (To prospectus dated July 27, 2021) 7,733,090 Shares of Common Stock Warrants to Purchase up to 2,706,561 Shares of Common Stock 2,706,561 Shares of Common Stock Underlying Warrants CytoSorbents Corporation We are offering directly to investors 7,733,090 shares (the “Shares”) of our common stock, $0.001 p |
|
| December 11, 2023 |
Exhibit 10.1 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K. SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 11, 2023, by and among CYTOSORBENTS CORPORATION, a Delaware corporation (the “Company”), and the investors identified on Schedule I hereto (e |
|
| December 11, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CYTOSORBENTS CORPORATION Warrant Shares: Issue Date: December 12, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 12, 2023 (the “Initial E |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Exhibit 99.1 CytoSorbents Reports Third Quarter 2023 Financial and Operational Results Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end. PRINCETON, N.J., November 9, 2023 — CytoSorbents Corporation (NASDAQ: |
|
| September 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 27, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 27, 2023 |
Exhibit 99.1 CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry PRINCETON, N.J., September 27, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adso |
|
| September 19, 2023 |
Employment Agreement, dated September 18, 2023, by and between the Company and Ms. Kathleen Bloch* Exhibit 10.1 Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K. Executive Employment Agreement This Executive Employment Agreement (the “Employment Agreement” or “Agreement”) is made and entered by and between Kathleen P. Bloch (the “Executive”), and CytoSorbents Medical, Inc., on behalf of itself, its parent Cyt |
|
| September 19, 2023 |
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer Exhibit 99.1 CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer PRINCETON, N.J., September 19, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 18, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 12, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 11, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 12, 2023 |
Exhibit 99.1 CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation In the first human retrospective study, CytoSorb and ex vivo lung perfusion prior to lung transplant increased in-hospital and one-year survival PRINCETON, N.J., September 11, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 28, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| September 1, 2023 |
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico Exhibit 99.1 CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico PRINCETON, N.J., September 1, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that Alexander D’Amico has resigned as the Compa |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2023 |
Exhibit 99.1 CytoSorbents Reports Second Quarter 2023 Financial and Operational Results Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points to 74% PRINCETON, N.J., August 1, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| August 1, 2023 |
Exhibit 10.1 BOS 48669274v2 SEVENTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS SEVENTH AMENDMENT to the Amended and Restated Loan and Security Agreement (this “Amendment”) is made effective as of May 16, 2023 (the “Seventh Amendment Date”) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”) and CYTOSORBENTS CORPORATION, a Delaware corporation an |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 19, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| July 19, 2023 |
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer Exhibit 99.1 CytoSorbents Press Release CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer PRINCETON, N.J., July 19, 2023 (GLOBE NEWSWIRE) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced the appointm |
|
| July 19, 2023 |
Employment Agreement, dated July 10, 2023, by and between the Company and Mr. Alexander D’Amico Exhibit 10.1 Executive Employment Agreement This Executive Employment Agreement (the “Employment Agreement” or “Agreement”) is made and entered by and between Alexander D’Amico (the “Executive”), and CytoSorbents Medical, Inc., on behalf of itself, its parent CytoSorbents Corporation, and all other affiliates and subsidiaries thereof (collectively, the “Company”), effective as of July 10, 2023. WH |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 7, 2023 |
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial Exhibit 99.1 CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial PRINCETON, N.J., July 7, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed enrollment of the pivotal Safe and Timely Antithr |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 2, 2023 |
Exhibit 99.1 CytoSorbents Reports First Quarter 2023 Results Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023 PRINCETON, N.J., May 2, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the in |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| April 26, 2023 |
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled Exhibit 99.1 CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled PRINCETON, N.J., April 20, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that its pivotal STAR-T (Safe an |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 20, 2023 |
CytoSorbents Announces Board Chairman Al W. Kraus To Retire Exhibit 99.1 CytoSorbents Announces Board Chairman Al W. Kraus To Retire PRINCETON, N.J., April 19, 2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its Chairman of the Board, Al W. Kraus, will retire |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2023 |
Consulting Agreement, dated March 31, 2023, by and between the Company and Ms. Kathleen P. Bloch. Certain information identified by [***] has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because such information is not material and is private or confidential. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2023 |
Exhibit 99.1 CytoSorbents Reports Fourth Quarter and Full Year 2022 Results Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of sales growth in 2023 PRINCETON, N.J., March 9,2023 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive |
|
| March 9, 2023 |
Exhibit 10.11 |
|
| March 9, 2023 |
Exhibit 21.1 CytoSorbents Corporation List of Subsidiaries Name Jurisdiction CytoSorbents Medical Inc.* Delaware CytoSorbents Europe GmbH* Germany CytoSorbents Switzerland** Switzerland CytoSorbents Poland Sp. z.o.o.** Poland CytoSorbents France SAS France CytoSorbents UK Limited*** United Kingdom *Wholly-owned subsidiary of CytoSorbents Corporation **Wholly-owned subsidiary of CytoSorbents Europe |
|
| March 9, 2023 |
Exhibit 10.30 BOS 48669274v2 SIXTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT to the Amended and Restated Loan and Security Agreement (this “Amendment”) is made effective as of March 8, 2023 (the “Sixth Amendment Date”) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”) and CYTOSORBENTS CORPORATION, a Delaware corporation and CY |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 CYTOSORBENTS CORPORATION (Exac |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2023 |
CTSO / Cytosorbents Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0704-cytosorbentscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: CytoSorbents Corp. Title of Class of Securities: Common Stock CUSIP Number: 23283X206 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate |
|
| February 7, 2023 |
CTSO / Cytosorbents Corp / Skylands Capital, LLC - CYTOSORBENTS CORP Passive Investment SC 13G 1 sky85269-cyto13g.htm CYTOSORBENTS CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoSorbents Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 23283X206 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2023 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| February 1, 2023 |
Exhibit 99.1 CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 PRINCETON, N.J., Janua |
|
| December 29, 2022 |
EX-99.1 3 tm2233609d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives PRINCETON, N.J., December 29, 2022 — CytoSorbents Corporation (NASDAQ: |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 29, 2022 |
Exhibit 10.1 FIFTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to the Amended and Restated Loan and Security Agreement (this ?Amendment?) is made effective as of December 28, 2022 (the ?Fifth Amendment Date?) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?) and CYTOSORBENTS CORPORATION, a Delaware corporation and CYTOSORBENTS M |
|
| November 16, 2022 |
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled Exhibit 99.1 CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled PRINCETON, N.J., November 14, 2022 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that 40 of the targeted 1 |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| November 3, 2022 |
Exhibit 99.1 CytoSorbents Reports Third Quarter 2022 Financial and Operational Results CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month PRINCETON, N.J., November 3, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprie |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
EX-10.1 2 ctso-20220930xex10d1.htm EX-10.1 Exhibit 10.1 Certain confidential information contained in this document has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Execution Version MARKETING AGREEMENT This Marketing Agreement (this “Agreement”), effective as of August 1, 2022 (the “Effective Date”), is by and between CytoSorbents Corporation, a corporation existing under the l |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact |
|
| October 6, 2022 |
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch Exhibit 99.1 CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch PRINCETON, N.J., October 7, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that its Chief Financial Off |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 27, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 28, 2022 |
Exhibit 99.1 CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey CytoSorb?, DrugSorb?-ATR, and ECOS-300CY? now cleared for manufacturing from this site PRINCETON, N.J., September 27, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purificat |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name |
|
| August 2, 2022 |
Exhibit 99.2 Joint Press Release on upcoming collaboration (FINAL FOR RELEASE) CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms · Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations · CytoSorb will be featured |
|
| August 2, 2022 |
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results Exhibit 99.1 CytoSorbents Reports Second Quarter 2022 Financial and Operational Results PRINCETON, N.J., August 2, 2022 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2022 |
Exhibit 99.1 CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb? PRINCETON, N.J., June 1, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and |
|
| June 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 1, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 4, 2022 |
Exhibit 99.1 CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago. Product gross margins were 80%. MONMOUTH JUNCTION, N.J., May 3, 2022 ? CytoSorbents Co |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 3, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 29, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2022 |
Exhibit 99.1 First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb?-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., April 29, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its |
|
| April 28, 2022 |
EX-99.1 2 tm2213873d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Highlights the Strategy of “Enhanced Lung Rest” Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress MONMOUTH JUNCTION, N.J., April 28, 2022 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood |
|
| April 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 28, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 22, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted b |
|
| April 14, 2022 |
Exhibit 99.1 CytoSorbents To Expand Direct Sales of CytoSorb? to the United Kingdom, the Sixth Largest Medical Device Market in the World MONMOUTH JUNCTION, N.J., April 14, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 14, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 7, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| April 7, 2022 |
Exhibit 99.1 CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program MONMOUTH JUNCTION, N.J., April 7, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of |
|
| April 5, 2022 |
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors Exhibit 99.1 CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors MONMOUTH JUNCTION, N.J., April 5, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents? Board of Directors as a new independent director, |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 1, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| March 17, 2022 |
Exhibit 99.1 CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM) MONMOUTH JUNCTION, N.J., March 17, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in t |
|
| March 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 17, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2022 |
Exhibit 21.1 ? CytoSorbents Corporation ? List of Subsidiaries ? Name Jurisdiction CytoSorbents Medical Inc.* Delaware CytoSorbents Europe GmbH* Germany CytoSorbents Switzerland** Switzerland CytoSorbents Poland Sp. z.o.o.** ? Poland CytoSorbents UK Limited*** ? United Kingdom ? *Wholly-owned subsidiary of CytoSorbents Corporation ? **Wholly-owned subsidiary of CytoSorbents Europe GmbH ? ***Wholly |
|
| March 10, 2022 |
Exhibit 4.1 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following description sets forth certain material terms and provisions of CytoSorbents? (?CytoSorbents,? ?we,? ?us,? and ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. ? DESCRIPTION OF CAPITAL STOCK ? The |
|
| March 8, 2022 |
Exhibit 99.1 CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook 2021 total revenue was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approximately 13% Y-Y to $33.8 million. 2022 marks the 10th anniversary of CytoSorb? commercialization MONMOUTH JUNCTION, N.J., March 8, 2022 ? CytoSorbents Corporation (NASDAQ |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 8, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2022 |
CTSO / Cytosorbents Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: CytoSorbents Corp. Title of Class of Securities: Common Stock CUSIP Number: 23283X206 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| February 1, 2022 |
Exhibit 99.1 First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb? to Restore Hemodynamic Stability in Patients with Refractory Septic Shock MONMOUTH JUNCTION, N.J., February 1, 2022 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification |
|
| January 24, 2022 |
Exhibit 99.1 New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents? Antithrombotic Drug Removal Technology MONMOUTH JUNCTION, NJ ? January 24, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 24, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| January 20, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 19, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| January 20, 2022 |
Exhibit 10.1 FOURTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to the Amended and Restated Loan and Security Agreement (this ?Amendment?) is made effective as of January 19, 2022 (the ?Fourth Amendment Date?) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?) and CYTOSORBENTS CORPORATION, a Delaware corporation and CYTOSORBENTS |
|
| January 20, 2022 |
Exhibit 10.2 Success Fee Letter CytoSorbents Corporation 7 Deer Park Drive Suite K Monmouth Junction, NJ 08852 January 19, 2022 Bridge Bank, a division of Western Alliance Bank 4370 La Jolla Village Drive Suite 305 San Diego, CA 92122 Attn: Bill Wickline Ladies and Gentlemen: Reference is herein made to that certain Amended and Restated Loan and Security Agreement (the ?Loan Agreement?), dated as |
|
| January 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 18, 2022 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| January 18, 2022 |
Exhibit 99.1 CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Preliminary Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth of approximately 13% from 2020. Cumulative CytoSorb treatments surpassed 162,000. MONMOUTH JUNCTION, NJ ? January 18, 2022 - CytoSorbents Corporation (NASDAQ: CTSO), |
|
| December 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 30, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| December 30, 2021 |
EX-1.1 2 tm2136586d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM December 30, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: CytoSorbents Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal ( |
|
| December 30, 2021 |
Up to $25,000,000 Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated July 27, 2021) Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| December 21, 2021 |
Exhibit 99.2 CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular MONMOUTH JUNCTION, N.J., December 21, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MH |
|
| December 21, 2021 |
Exhibit 99.1 CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb? in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) MONMOUTH JUNCTION, N.J., December 20, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purificatio |
|
| December 21, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissi |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| November 4, 2021 |
Exhibit 99.1 CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results Third Quarter 2021 total revenue was $9.8 million, including product sales of $8.9 million. Core non-COVID-19 product sales increased 3% Y-Y to approximately $7.8 million. MONMOUTH JUNCTION, N.J., November 4, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi |
|
| October 21, 2021 |
CytoSorbents Comments on REMOVE Study Presentation Exhibit 99.1 CytoSorbents Comments on REMOVE Study Presentation MONMOUTH JUNCTION, N.J., October 20, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb?1 blood purification, makes additional comments on the investigator-initiated REMOVE study following the formal presentation of trial results |
|
| October 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| October 15, 2021 |
Exhibit 99.1 First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR? Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., October 14, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary |
|
| October 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| October 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 12, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commissio |
|
| October 13, 2021 |
Exhibit 99.1 CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance Preliminary third quarter 2021 total revenue was $9.7 million, including product sales of $8.9 million. Preliminary core non-COVID-19 product sales increased 4% Y-Y to approximately $7.8 million. MONMOUTH JUNCTION, N.J., October 12, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), |
|
| October 13, 2021 |
Exhibit 99.2 CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR? Antithrombotic Removal System During Urgent Cardiothoracic Surgery The U.S. STAR-D and already recruiting STAR-T randomized controlled pivotal trials are intended to establish DrugSorb-ATR as a single, easy-to-use solution f |
|
| October 8, 2021 |
Exhibit 99.1 CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference MONMOUTH JUNCTION, N.J., October 7, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the pub |
|
| October 8, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| September 14, 2021 |
Exhibit 99.1 CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb? in Critically Ill Patients with COVID-19 Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients MONMOUTH JUNCTION, N.J., September 14, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commis |
|
| September 10, 2021 |
Exhibit 99.1 CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR? Antithrombotic Removal System During Urgent Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., September 10, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive car |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 10, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commiss |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 30, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
|
| September 1, 2021 |
Exhibit 99.1 CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb? Adsorber and PerLife? Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress MONMOUTH JUNCTION, N.J., and BOLOGNA, ITALY, August 30, 2021 ? CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood p |
|
| September 1, 2021 |
EX-99.2 3 tm2126800d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Topline Results from CytoSorbents’ U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) 90-day ICU Mortality was 27% with ECMO + CytoSorb in CTC Registry Data Presented on Day 1 of the International Symposium on Intensive Care and Emergency |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 12, 2021 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-36792 98-0373793 (State or other jurisdiction of incorporation) (Commission |
